Skip to main content

Table 2 Index hospitalization characteristics of study patients; by clopidogrel duration (9, 12, 15 months) analysis

From: Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome

 

9-months

  

12-months

  

15-months

  
 

Discontinuous users (n = 292)

Continuous users (n = 452)

p*

Discontinuous users (n = 382)

Continuous users (n = 317)

p*

Discontinuous users (n = 489)

Continuous users (n = 164)

p*

STEMI

60 (20.6%)

124 (27.4%)

0.03*

95 (24.9%)

80 (25.2%)

0.91

127 (26.0%)

35 (21.3%)

0.23

NSTEMI

22 (7.5%)

76 (16.8%)

<0.001*

41 (10.7%)

52 (16.4%)

0.03*

62 (12.7%)

26 (15.9%)

0.30

Non-elective PCI

43 (14.7%)

91 (20.1%)

0.06

69 (18.1%)

57 (18.0%)

0.98

89 (18.2%)

27 (16.5%)

0.61

IABP use

3 (1.0%)

8 (1.8%)

0.54

4 (1.1%)

7 (2.2%)

0.22

7 (1.4%)

3 (1.8%)

0.72

GP IIb IIIa inhibitors

7 (2.4%)

15 (3.3%)

0.47

12 (3.1%)

10 (3.2%)

0.99

15 (3.1%)

7 (4.3%)

0.19

Number of diseased vessels

1.90 ± 0.85

2.03 ± 0.85

0.04*

1.91 ± 0.86

2.06 ± 0.85

0.02*

1.93 ± 0.86

2.04 ± 0.84

0.19

Multivessel PCI

93 (31.9%)

157 (34.7%)

0.42

115 (30.1%)

119 (37.5%)

0.04*

151 (30.9%)

68 (41.5%)

0.01*

Total occlusion

76 (26.0%)

153 (33.9%)

0.02*

106 (27.8%)

108 (34.1%)

0.07

142 (29.0%)

56 (34.2%)

0.22

Ostium lesion

18 (6.2%)

42 (9.3%)

0.13

24 (6.3%)

28 (8.8%)

0.20

29 (5.9%)

19 (11.6%)

0.01*

Bifurcation lesion

11 (3.8%)

25 (5.5%)

0.27

12 (3.1%)

18 (5.7%)

0.10

17 (3.5%)

10 (6.1%)

0.14

Location of stent

         

 RCA

92 (31.5%)

162 (35.8%)

0.22

118 (30.9%)

124 (39.1%)

0.02*

161 (32.9%)

61 (37.2%)

0.32

 LAD

177 (60.6%)

281 (62.2%)

0.67

238 (62.3%)

195 (61.5%)

0.83

303 (62.0%)

104 (63.4%)

0.74

 LCX

78 (26.7%)

128 (28.3%)

0.63

99 (25.9%)

91 (28.7%)

0.41

131 (26.8%)

52 (31.7%)

0.22

 LM

12 (4.1%)

27 (6.0%)

0.27

13 (3.4%)

19 (6.0%)

0.10

18 (3.7%)

12 (7.3%)

0.05*

Number of stents

         

 1 stent

159 (54.5%)

219 (48.5%)

0.11

206 (53.9%)

147 (46.4%)

0.08

261 (53.4%)

67 (40.9%)

0.02*

 ≥ 2 stents

122 (41.8%)

222 (49.1%)

163 (42.7%)

162 (51.1%)

215 (44.0%)

91 (55.5%)

At least 1 DES

185 (63.4%)

369 (81.6%)

<0.001*

252 (66.0%)

271 (85.5%)

<0.001*

350 (71.6%)

140 (85.4%)

<0.001*

 Paclitaxel

53 (18.2)

103 (22.8)

0.13

72 (18.9)

75 (23.7)

0.12

91 (18.6)

44 (26.8)

0.02*

 Sirolimus

76 (26.0)

134 (29.7)

0.28

103 (27.0)

94 (29.7)

0.43

139 (28.4)

49 (29.9)

0.72

 Zotarolimus

49 (16.8)

105 (23.2)

0.03*

65 (17.0)

84 (26.5)

0.002*

95 (19.4)

43 (26.2)

0.07

 Everolimus

12 (4.1)

45 (10.0)

0.003*

19 (5.0)

35 (11.0)

0.003*

35 (7.2)

14 (8.5)

0.56

 EPC-capturing

11 (3.8)

13 (2.9)

0.50

15 (3.9)

7 (2.2)

0.20

17 (3.5)

4 (2.4)

0.62

Total stent length (mm)

39.6 ± 25.1

45.5 ± 30.2

0.01*

39.7 ± 24.9

46.9 ± 31.1

0.001*

41.4 ± 26.8

49.0 ± 32.7

0.01*

Min. stent diameter (mm)

3.04 ± 0.43

2.96 ± 0.47

0.03*

3.03 ± 0.44

2.95 ± 0.46

0.03*

3.0 ± 0.4

3.0 ± 0.5

0.27

  1. *p-value <0.05.
  2. STEMI = ST-elevation myocardial infarction, NSTEMI = non ST-elevation myocardial infarction, PCI = percutaneous coronary intervention, IABP = intra-aortic balloon pumping, RCA = right coronary artery, LAD = left anterior descending, LCX left circumflex, LM = left main, EPC = endothelial progenitor cell.